All In Biotech

Drug Trial Radar · NCT07938606

MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)

A Phase Ib/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Pediatric Patients Aged 6 to 12 Years With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2027

Study completion Mar 2028

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ib/II Study of MG-K10 in Pediatric Patients (6-12 Years) with Moderate to Severe Atopic Dermatitis Primary Objective: To evaluate the safety of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe atopic dermatitis (AD). Secondary Objectives: To evaluate the pharmacokinetic (PK) characteristics, preliminary efficacy, pharmacodynamic (PD) characteristics, and immunogenicity of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe AD.

Conditions

  • Atopic Dermatitis

Interventions

  • Emollient (moisturizer)Other

    Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection

  • MG-K10 humanized monoclonal antibody injectionDrug

    Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse eventsTime frame: Up to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.